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Abstract Rhabdomyosarcoma (RMS) is the commonest
paediatric soft-tissue sarcoma constituting 3–5% of all malig-
nancies in childhood. RMS has a predilection for the head and
neck area and tumours in this location account for 40% of all
childhood RMS cases. In this review we address the clinical
and imaging presentations of craniofacial RMS, discuss the
most appropriate imaging techniques, present characteristic
imaging features and offer an overview of differential
diagnostic considerations. Post-treatment changes will be
briefly addressed.
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Introduction
Rhabdomyosarcoma (RMS) is the commonest paediatric
soft-tissue sarcoma, constituting 3–5% of all malignancies
in childhood [1]. RMS has a predilection for the head and
neck area and tumours in this location account for 40% of
all childhood RMS cases, making it the second most
common primary malignant head and neck tumour in
children after malignant lymphoma [2]. RMS is a high-
grade, malignant mesenchymal tumour probably originating
from primitive mesenchymal cells that can arise anywhere
in the body, including sites where striated muscle is not
normally found.
RMS is predominantly a disease of childhood and occurs
somewhat less frequently in adolescents. The mean age at
diagnosis is 5–6 years and 72–81% of patients are younger
than 10 years [3, 4]. In 5–6.5% the child is younger than
1 year and only 2% of RMS manifests at birth [5, 6]. There
is a slight male predominance, M:F=1.3:1.
Clinical symptoms vary and depend on the location of
the primary tumour and the presence or absence of
metastases [7, 8]. Head and neck RMS (HNRMS) can
present indolently, with nonspecific or minimal signs and
symptoms, leading to a delay in diagnosis. For example,
chronic otitis or nasal obstruction may be the presenting
symptom in a nasopharyngeal location whereas persistent
headache may be a sign of intracranial tumour extension.
More ominous signs are cranial nerve palsies in para-
meningeal locations indicating involvement of the skull
base. Orbital tumours are detected relatively early, due to
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prognosis of orbital RMS. Although proptosis is the result
of an intra-orbital tumour location, it can also be caused by
orbital invasion from another compartment. A prolonged
duration of common symptoms or a rapidly growing mass
should arouse suspicion of a malignant lesion.
Three main groups of RMS are recognized, based on
histological morphology: embryonal, alveolar and pleomor-
phic, of which the former two mainly occur in children and
the last only in adults [8]. The embryonal type (eRMS)
accounts for about 70% of cases, affects somewhat younger
patients and has a better prognosis. Alveolar RMS accounts
for about 15%, is seen in older children and has a worse
prognosis [9, 10]. Three different primary locations of
HNRMS are recognized: parameningeal (PM), non-
parameningeal head and neck (NPM) and orbital (ORB),
which are involved in approximately 50%, 25% and 25% of
cases respectively (Table 1)[ 9]. Parameningeal location
carries a worse prognosis [5-year overall survival (OS) 64–
73%] compared to NPM and ORB locations (5-year OS
64–80% and 85–88% respectively) for at least two reasons
[4, 9, 11]. Firstly, the deep location may conceal a tumour
that remains clinically silent unless it has grown to a
considerable size and becomes visible from the outside, and
secondly because the PM location is very close to the skull
base and contains vital structures such as the internal
carotid artery, internal jugular vein and multiple cranial
nerves, precluding oncological resection. A third reason
might be that PM RMS has a different biological
composition. In a series of 526 children with PM RMS,
Raney et al. [4] found cranial nerve palsy and/or cranial
base bony erosion in 33% of children at diagnosis, while
35% presented with intracranial extension in contiguity
with the primary tumour. Only 32% had no signs of
meningeal involvement.
Imagingprovidescrucialinformationearlyinthediagnosis
by defining the exact location of the lesion and offering a
differential diagnosis, thereby guiding the subsequent steps of
the diagnostic analysis and follow-up. Furthermore it makes
an essential contribution in the staging of HNRMS, showing
the size and location of the tumour and its extension into
adjacent compartments, as it can demonstrate the presence or
absence of intracranial extension, involvement of cranial
nerves, cranial base bony erosion, orbital involvement and
encasement of the carotid or vertebral arteries [12, 13].
The detection of lymph node metastases has also become
more accurate with modern imaging techniques, as has the
demonstration of distant metastases [14–19].
Sometimes imaging helps to guide a biopsy procedure by
showing the best route to obtain representative material.
Follow-up imaging is important to monitor tumour
regression during or after completion of chemotherapy
and to detect tumour recurrence [19–21].
In this review we address the clinical and imaging
presentations of craniofacial RMS, discuss the most
appropriate imaging techniques, present characteristic im-
aging features and offer an overview of differential
diagnostic considerations. Post-treatment changes will be
briefly addressed.
Imaging techniques
MRI
Unlike small superficial mass lesions, which are well-
demonstrated by US, tumours of the head and neck in the
paediatric population are currently best depicted with MRI.
Superior soft-tissue contrast, excellent spatial resolution,
multiplanar imaging and the absence of potentially harmful
ionizing radiation make MRI a powerful instrument for
accurate local staging. With dedicated coils, MRI can cover
the whole area comprising the skull base and intracranial
compartment as well as the face, the orbits and the neck,
thereby assessing local extension of the primary tumour and
involvement of regional nodes. Whole-body MRI
(WBMRI) may replace bone scintigraphy in the coming
years to assess distant metastases [14, 15].
Although the advantage of MRI in this young patient
population is its lack of ionizing radiation exposure, a
major drawback is the long examination time (up to 30–
45 min) and the fact that MRI is extremely sensitive to
motion artefacts. Therefore most children younger than 6–
7 years need sedation or general anaesthesia during their
MRI examination.
MRI protocols are reproducible and therefore MRI is
suitable to assess response during chemotherapy, to depict
residual mass lesions after completion of therapy and to
detect and assess loco-regional and distant recurrent disease
during follow-up.
MRI techniques
Routine spin-echo (SE) T1- and T2-weighted sequences
before and after intravenous (IV) contrast administration in
axial, coronal and/or sagittal planes are crucial for evalu-
ation of a head and neck tumour in children.
Diffusion-weighted imaging (DWI) seems to be a
promising new tool to differentiate benign from malignant
lesions in the paediatric population [12, 22]. However, most
of the literature concerns adult patients with head and neck
malignancies and there still is some controversy about its
accuracy [23–25]. DWI is reported to be superior to
conventional methods in recognizing malignant neck nodes
in adult patients with squamous cell carcinoma of the head
and neck [18, 26, 27]. It has also been reported to be a
1724 Pediatr Radiol (2010) 40:1723–1738valuable tool in the analysis of post-treatment residual
disease, where DWI may differentiate postoperative scar-
ring or necrosis from residual viable or recurrent tumour
[28]. At this moment no evidence-based data are available
specifically concerning DWI in HNRMS.
Gradient-echo (GRE) sequences, often used in brain
imaging, are short three-dimensional sequences with thin
(<1 mm) slices but are not very useful in the head and neck
area due to artefacts from air-bone interfaces. Signal contrast
between tumour and normal soft tissues is reduced, especially
in the orbit, resulting in poor lesion conspicuity. Major
advantages include their multiplanar reconstruction possibility.
Volumetric interpolated breath-hold examination (VIBE
—Siemens, Erlangen, Germany) is a T1-W, 3-D Flash, fat-
saturated sequence with a very homogeneous fat saturation
effect. It is used after IV contrast, is very fast to acquire
(30 s) and 3-D reconstructions are possible from the
original acquisition plane. Therefore, VIBE may be of help
to detect subtle skull base abnormalities and perineural
tumour spread [29].
1H-spectroscopy is an MRI technique that has been used
to identify brain tumours and to differentiate malignant
from benign disease. Tissue volumes of at least 1 cm
3 are
sampled and analyzed for spectral elements. However, the
presence of many different tissues in even a small volume
sample in the head and neck area still limits the use of MR
spectroscopy on a routine basis.
Dynamic contrast-enhanced MR (DCE-MRI) imaging is a
technique to assess tumour vascularity in vivo. It has been
applied to differentiate benign from malignant disease, where
some overlap exists between highly vascular benign tumours
andmalignanciesandhasbeenshowntobeusefultocorrectly
predict responsetotherapy inhistologicallyprovensoft-tissue
and bone sarcomas [12, 30]. Early, rapidly progressive
enhancement was correlated histologically with residual
viable tumour. Late, gradual enhancement or the absence of
enhancement was correlated with necrosis or granulation
tissue [31]. DCE-MRI may be of interest in assessing the
nature of a residual mass after completion of treatment [32].
Multidetector CT (MDCT)
With modern spiral CT scanners examination time is
reduced from minutes to seconds. Multiplanar reconstruc-
tions and the automatic tailoring of machine settings
according to the volume of the patient have led to a
substantial reduction of radiation dose compared to the
former single-slice scanners but it is still not zero [33].
In patients with RMS, CT is mainly performed to assess
the absence or presence of lung metastases [8].
When using CT we must be aware that exposure to
ionizing radiation may theoretically induce a second poten-
tially fatal cancer in children who have already manifested a
tendency to harbour cancer [34, 35].
US
US is probably the most commonly applied cross-sectional
imagingtechniqueinchildren.Unfortunately,UScannot reach
the deep compartments of the face, hampered as it is by bone
and air, and therefore US has severe limitations for the
evaluation of primary head and neck tumours. However, US
may be invaluable to obtain an initial quick confirmation of a
suspectedmasslesionandofitscystic,solidorvascularnature.
Table 1 Locations of HNRMS
a
PM Non-PM Orbital
25–50% 25% 25%
Nasopharynx Scalp Eye lids
PPS/MS/pterygopalatine
fossa
Parotid Lacrimal
gland
Nasal cavity and paranasal
sinuses
Oral cavity Extra-ocular
muscles
Middle ear Larynx Globe
Orbital tumours with bone
erosion
Oropharynx Orbit
Involvement of vessels
(carotid artery, jugular vein)
and cranial nerves
with direct intracranial
connection
Cheek
All tumours with cranial
nerve paresis
Hypopharynx
All tumours with intracranial
and/or intraspinal extension
Thyroid/
parathyroid
CSF tumour-cell-positive
patients
Neck
aAfter EpSSG 2005 [3, 9, 76]
Table 2 MRI protocol for HNRMS at 1.5-T
Head-neck coil
Axial SE T1-W, SE T2-W
Coronal SE T1-W; optional: sagittal SE T1-W
After IV gadolinium: coronal without fat saturation
axial, coronal, sagittal with fat saturation
Slice thickness: ≤3m m
Field of view 180–200
DWI-echo planar imaging or non-EPI
Optional:
T1- and/or T2-W fat-saturated sequences (STIR, SPIR)
Contrast-enhanced GRE sequences (VIBE)
General anaesthesia in young children: <7 years
For orbital RMS it is recommended to add fat saturation in all
contrast-enhanced series and to incline the sagittal series parallel to
the optic nerve
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US is very accurate in delineating neck masses and
enlarged or otherwise suspicious lymph nodes in children
with HNRMS and is useful to guide fine-needle aspiration
cytology (FNAC). For primary tumours open biopsies
under general anaesthesia are preferred and in the same
session FNAC of suspicious nodes can be performed. Often
children are referred from another centre, where a biopsy of
the primary tumour has already been performed. Those
children will have their staging under general anaesthesia,
including a bone marrow puncture and trephine, and a
lumbar puncture for PM cases; the same anaesthesia can
then be used to perform FNAC of suspicious nodes, if
present.
Bone scintigraphy
Although bone scintigraphy is currently required as part of
the work-up of children with RMS [European paediatric
soft-tissue sarcoma Study Group (EpSSG) and Children’s
Oncology Group (COG) protocols], there is doubt about its
yield in routine use, which is said to be very low [14, 36].
Bone scintigraphy is most accurate for osteoblastic metas-
tases, whereas PET-CT is most effective in demonstrating
osteolytic metastases. Therefore in future protocols bone
scintigraphy might be considered for symptomatic or high-
risk patients only.
PET-CT
18FDG PET-CT allows examination of the entire body in one
session and can detect not only the primary tumour but also
regional and distant metastatic disease [14]. Tateishi et al. [37]
reported on 35 patients in a blinded retrospective study, in
whom PET-CT had the same accuracy in staging the primary
tumour (T-stage) and regional lymph nodes (N-stage) as
conventional imaging (radiographs, whole-body CT and/or
MRI) [37]. However, distant metastases (M-stage) were much
better appreciated by PET-CT compared to MRI, CT or bone
scintigraphy. In a non-blinded retrospective study Klem et al.
[38] found that PET did detect occult lymph node metastases
in the neck not identified by other imaging techniques.
Fig. 1 Masticator space eRMS in
a 4-year-old boy presenting with a
rapidly progressive right side pre-
auricular mass. a Coronal SE T1-W
image without IV contrast demon-
strates obliteration of the fat planes
(arrow)o ft h eM Sa n dt h eP P Sa n d
o ft h es p h e n o i dw i n go nt h er i g h t
side [compare to the normal left
side (white arrow)]. Also note
abnormal configuration and signal
of the right mandible, better shown
on the axial SE T1-W images (b).
b Axial SE T1-W image shows
tumour bulging through the man-
dible underneath the masseter
muscle with preservation of the fat
plane (arrowhead). The PPS is
compressed and the fat is displaced
posteriorly and medially (arrow),
indicating that the origin of the
tumour is not in the PPS but in the
MS. Extension of tumour through
the stylomandibular foramen into
the parotid gland (small arrow). c
The mass is of high signal intensity
throughout on axial SE T2-W
sequence. d Coronal SET1 image
after i.v. contrast: heterogeneous
enhancement with many necrotic
areas. Tumour extention through
the foramen ovale into the right
cavernous sinus (large arrow).
Note also subtle dural enhancement
(small arrow), which was inter-
preted as tumour extension, but
might have been reactive changes
only, according to thickness < 5mm
1726 Pediatr Radiol (2010) 40:1723–1738However, the detection of bone metastases by PET was,
surprisingly, equal to conventional techniques (MRI, CT,
radiograph). For the evaluation of lymph node metastases,
Völker et al. [17] found a higher sensitivity of FDG-PET
compared to conventional imaging, 88% and 62% respec-
tively. This group also showed that FDG-PET correctly
identified all bone metastases in 10 patients, whereas
conventional imaging was falsely negative in 3 patients.
Whether WBMRI or PET-CT should be used in routine
staging procedures in the paediatric population is still unclear.
Only a prospective clinical trial implementing both imaging
techniques combined with bone scintigraphy will be able to
answer this question. In our clinic we do not perform PET-CT
on a routine basis in children with HNRMS, due to the
radiation exposure and less accurate performance in assessing
the primary tumour. In our clinic, only children with an
increased risk of distant metastases are considered as
candidates for low-dose PET-CT or WBMRI. Most children
with metastatic disease are old enough to co-operate well;
younger or uncooperative children are sedated using chloral
hydrate and closely monitored.
Staging HNRMS
With continued improved survival of children with RMS,
correct assessment of the disease at presentation could lead
to significant clinical benefit.
Accurate staging, therefore, has become a major goal
before choosing the optimal treatment strategy in children
with HNRMS [8, 38]. Uniform staging is important in
comparing results from different co-operative groups as it
may lead to different treatment stratifications and protocols
in future trials, aiming to continuously improve treatment
results. The main staging system is the postsurgical system
developed by the Intergroup Rhabdomyosarcoma Study
Group (IRSG), which is currently used by both EpSSG and
COG [8].
Primary location (T)
A routine MR imaging protocol (Table 2) includes SE
T1-W and SE T2-weighted axial, coronal and sagittal
images before and after intravenous (IV) contrast admin-
istration. Axial and coronal planes are used for optimal
assessment of local extension and invasion of adjacent
compartments, whereas coronal and sagittal contrast-
enhanced images address questions about involvement of
the skull base and intracranial (dura, brain) and/or
perineural extension (Figs. 1 and 2). Additional DWI
series are recommended in all patients.
Imaging must assess the origin and local extension of the
primary tumour, its size (in three dimensions, in cm), the
presence or absence of tumour extension beyond the skull
base, invasion of the anterior, middle and posterior cranial
fossa, abnormal dural enhancement, perineural enhance-
Fig. 2 Four-year-old girl, presenting with a right side preauricular
mass and cranial nerve palsy (ptosis). A huge eRMS originating
within the MS was found with involvement of the greater wing of the
sphenoid bone and orbital apex on the right side, with massive
perineural extention along the 2nd and 3rd branches of the right
trigeminal nerve and involvement of the cisternal portion. a Axial
contrast-enhanced SE T1-W image shows a mass within the masticator
space (small arrow), abnormal enhancement of the sphenoid wing
(arrowhead), the clivus (white arrow) and multiple masses along the
2nd branch of the right trigeminal nerve (pterygopalatine fossa,
foramen rotundum, cavernous sinus) extending into the posterior fossa
with involvement of the cisternal portion of the trigeminal nerve
(large arrow). b Coronal contrast-enhanced SE T1-W image of the
same patient, shows involvement of the right MS, along the temporalis
muscle (large arrowhead), into the masseter muscle. Tumour extends
into the foramen rotundum (small arrowhead), the sphenoid wing
(small arrow) with massive dural invasion (>5 mm) (large arrow) and
invasion of the clivus (white arrow)
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(Table 3).
Perineural spread
Perineural spread is said to occur when abnormal enhance-
ment along cranial nerves (CN) is observed, either in
isolation or in combination with nodular thickening, in
patients with malignant head and neck tumours [39–43].
Most often involvement of the trigeminal nerve branches
and/or the facial nerve is seen, but any other cranial nerve
may be involved.
Perineural involvement of the trigeminal nerve may be
identified by abnormal enhancement along its course from
the brainstem into the cavernous sinus. From this point
abnormal enhancement along the three trigeminal branches
(V-1, V-2, V-3) should be looked for carefully: first the
ophthalmic nerve (V-1) in the upper quadrant of the orbit,
then the maxillary nerve (V-2) within the foramen rotun-
dum, the infraorbital fissure, along the lateral floor of the
orbit (infraorbital sulcus) through the infraorbital foramen
and finally the mandibular nerve (V-3) within the foramen
ovale, the masticator space (MS) and the mandibular canal
up to the mental foramen. It is helpful to compare with the
uninvolved side to detect subtle asymmetry. Perineural
enhancement also may be seen along the facial nerve as far
as the inner auditory canal. The pterygopalatine fossa,
being an anatomical crossroad, also should be scrutinized
for obliteration of normal fat planes and abnormal enhance-
ment of the pterygopalatine ganglion, the palatine nerves as
well as the vidian nerve, which extends from the pterygo-
- Origin: PM; head and neck; orbit
- Extension adjacent compartments:
PPS
MS
Pterygopalatine fossa
Orbit
Paranasal sinuses
- Extension foramen ovale, foramen rotundum, other
- Cavernous sinus involvement
- Perineural enhancement: N-V, N-VII, other
- Intracranial extension:
Anterior cranial fossa
Middle cranial fossa
Posterior cranial fossa
- Dural enhancement: < or >5 mm thickness
- External auditory canal/middle ear
- Mastoid/internal auditory canal
- Maximum sizes in 3 dimensions in cm
- Suspicious lymph nodes
- Retropharyngeal space
- Neck
Bilateral/unilateral
Homolateral/contralateral
- Bone changes (skull base, mastoid, petrous bone, mandible, maxilla, orbit, zygoma, skull vault)
Table 3 Checklist for the radi-
ology report
PM: consider additional CT in
selected patients
Fig. 3 One-year-old boy presenting with a rapidly growing mass from
the right nasal ostium. Sagittal T2-W MRI shows a well-defined,
sausage-like lesion with heterogeneous signal intensity (arrows). The
high signal intensity of the ethmoid cells was interpreted as obstructed
secretions rather than direct tumour invasion in the absence of obvious
destruction of the ethmoid air cells. At surgery, after three courses of
chemotherapy, no tumour was found in the ethmoids; a small residual
tumour was adherent to the skull base, not identified on preoperative
MRI, classifying the tumour as a PM location
1728 Pediatr Radiol (2010) 40:1723–1738palatine ganglion through the vidian canal posteriorly and
communicates with the greater petrosal nerve.
In one of our patients we noticed abnormal enhancement
of the thickened CN V-2 within the foramen rotundum at
diagnosis. During chemotherapy the swelling regressed but
enhancement lasted for many years during follow-up
without clinical symptoms, probably due to mild inflam-
matory changes (chronic neuritis). It seems therefore that
enhancement per se is not always due to tumour extension
and cautious interpretation of persistent abnormal enhance-
ment, without concomitant increase in volume and in the
absence of other signs of recurrent disease, is advised.
Lymph nodes (N)
The incidence of loco-regional metastatic lymph nodes in
HNRMS is low, about 10–20%, tumour spread mainly
being by way of vascular metastases in sarcomas [4, 13,
44].
Enlarged lymph nodes may normally be observed in the
retropharyngeal space and in the neck in children and
therefore size criteria are less reliable than in adults.
Unfortunately, no evidence-based papers regarding imaging
appearance of malignant neck nodes in children exist and
the findings in adult patients regard mostly patients with
squamous cell carcinoma and cannot be used for children
with sarcomas. There are, however, some important,
empirical imaging findings in children with HNRMS. A
hypoechoic, rounded neck node with obliteration of the fat
centre is suspicious of a metastatic node and warrants fine-
needle aspiration biopsy. Central necrosis is commonly
seen in infectious disease (tuberculosis, cat-scratch disease)
but rarely in malignant tumours.
For the assessment of lymph node metastases US, if
needed with additional US-guided fine-needle cytology,
remains our standard technique.
Distant metastases (M)
About 15% of children with HNRMS will have distant
metastases at diagnosis [45]. Lung metastases are best
identified with multidetector CT (MDCT), although it may
Fig. 4 Left external auditory canal (EAC) location in a 10-year-old
girl with itching and pain of the left ear for 2 weeks and conductive
hearing loss. No history of acute or chronic middle ear disease. At
clinical examination a soft-tissue mass was seen, completely filling the
EAC. a CT demonstrates unilateral complete opacification of the EAC
and the middle ear cavity on the left side with erosion of the bony
walls medially (arrow). The carotid canal wall is intact as is the
posterior aspect of the mastoid. Note the asymmetrical pneumatisation
of the petrosal apex, a normal variant. b Coronal T1-W MRI shows an
expansile mass within the EAC (arrows) extending into the tympanic
cavity and slow flow within the left (and right) internal jugular vein
(arrowheads). c Axial contrast-enhanced SE T1-W image shows that
the mass strongly enhances and has invaded the middle ear cavity
(large arrow). Without fat saturation the exact tumour extension is
difficult to assess at the petrosal apex. In this case CT was helpful to
exclude apical invasion (a) and confirm asymmetrical pneumatisation
of the apices (small arrows)
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nodules [8]. Bone metastases and metastases in other parts
of the body are now best assessed by PET-CT or WBMRI
because these techniques include the whole body, bone as
well as soft tissues and parenchymal organs [14, 37, 38].
Equivocal lesions may be further evaluated by US or CT.
Brain metastases from HNRMS are rare and are mostly
seen in patients with recurrent disease and distant metastatic
disease in other parts of the body [46]. Imaging of the brain
in search for brain metastases therefore is recommended
only in clinically suspected patients [47].
Imaging characteristics in HNRMS
Most HNRMS are solitary, unilateral bulky lesions,
although multifocal primary HNRMS has been reported
[48].
Spin-echo T1-W sequences offer excellent contrast
between the tumour and surrounding (obliterated) fat planes
as well as the skull base in axial and coronal planes. SE T2-
W sequences may show a large variety of signal intensities
(SI) of RMS in different patients and extremely low or high
or intermediate SI, compared to muscle may be seen [13,
48–52]. Some tumours may appear relatively homogeneous
and others are frankly heterogeneous, probably correlating
with cellularity, tumour matrix and necrosis [22, 24, 25].
Understanding these MRI findings by correlating imaging
with histopathological findings is subject of study in our
group and will be reported elsewhere.
Although HNRMS may show a variety of enhancement
patterns after IV contrast administration, the majority show
moderate, homogeneous enhancement. Non-enhancing areas
may berecognized after IV contrastadministration, represent-
ing central necrosis or cavitation [49]. There seems to be no
pathognomonic MRI appearance of HNRMS.
Tumour locations and specific imaging concerns
PM HNRMS
Parameningeal locations are in direct or near contact with
the skull base. Tumours may originate from the nasophar-
ynx (NP), the parapharyngeal space (PPS), the MS
(formerly called the “infratemporal fossa”), the nasal cavity
(Fig. 3), paranasal sinuses, the mastoid or the middle ear
(Table 1) (Fig. 4). It may be difficult to assess the origin of
a large lesion, but defining the centre of the bulk and
analysing the way in which normal structures are displaced
may help in defining the correct compartment [53].
PMRMS may show earlier spread to the skull base and
intracranial compartment compared to other locations and
accurate assessment of the local extent is one of the
principal goals of imaging. Survival is worse and treatment
options differ when there is skull base involvement or
intracranial tumour extension [4, 54].
Skull base involvement may be well identified on non-
contrast-enhanced SE T1-W sequences. Invasion of the
sphenoid bone and the clivus and also the pterygoid bone
and pterygoid plates may occur (Fig. 1). When a tumour is
located in the masticator space the mandible and temporo-
mandibular joint (TMJ) may be at risk. Tumour extension
Fig. 5 Fourteen-year-old boy with a large MS tumour (eRMS).
Coronal contrast-enhanced SE T1-W image shows extension through
the massively enlarged foramen ovale into the cavernous sinus on the
right side and asymmetry of the internal carotid artery by tumour
compression (arrowhead). Note heterogeneous enhancement with
strands of non-enhancing tissue within the tumour mass. There is
also compression of the temporal lobe (arrow). No pathological
enhancement of the adjacent brain, therefore no suspicion of direct
tumour invasion of the brain
Fig. 6 Non-PM eRMS in a 7-year-old boy at the left side of the nose
(open arrow). Axial SE T2-W image shows the small, superficial
lesion with no deep extension. Fluid level (white arrow) represents
haemorrhage after biopsy
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disappearance of normal fat planes and for abnormal contrast
enhancement, comparing with the normal, non-involved side.
Contrast-enhanced images show pathological enhance-
ment of the tumour, which may become more obvious when
fat saturation is added. Subtle perineural extension becomes
more obvious after IV contrast administration. Asymmetrical
enlargement of the cavernous sinus with abnormal enhance-
ment in the skull base foramina may be a subtle sign of
intracranial tumour extension along the trigeminal nerve
branches (see below).
Encasement of the internal carotid artery (Fig. 5) may be
seen as well as compression of the jugular vein. Perivas-
cular enhancement along the internal carotid artery near the
skull base suggests tumour extension beyond the extracra-
nial compartments and careful reappraisal of findings must
be considered.
Non-PM HNRMS
These tumours are located in all other compartments except
the orbit (Table 1). Careful assessment of local extension of
oropharyngeal or oral cavity RMS into adjacent compart-
ments, e.g., the PPS or MS, is mandatory, because this may
change a low-risk location to a high-risk PM location.
Intranasal locations may be purely non-PM (Fig. 6) but may
become PM when the tumour abuts the skull base (Fig. 3).
Bone invasion of the hard palate may cause perineural
spread along the palatine nerves and from there retrograde
tumour extension may occur along the trigeminal branches
and the vidian nerve into the cranial compartment, thereby
altering the prognosis into a less favourable PM location.
Parotid HNRMS per se falls under the non-PM group,
but in case of involvement of the facial nerve or extension
Table 4 Differential diagnostic considerations
Benign Malignant
PM PM
Haemangioma/lymphangioma Malignant lymphoma
Juvenile angiofibroma Nasopharyngeal carcinoma
Schwannoma Hemangioendothelioma
Plexiform neurofibroma Ewing sarcoma
Aneurysmal bone cyst PNET
Giant cell granuloma Osteosarcoma
Neurinoma Metastasis
Parotid tumour
Non-PM head and neck Non-PM head and neck
Reactive lymph nodes Metastasis (neuroblastoma)
Mucocele Other:
Nasal polyp Extra-skeletal mesenchymal
Ossifying fibroma Chondrosarcoma
Lateral neck cyst Fibrosarcoma
Medial neck cyst Synoviosarcoma
Teratoma
Ectopic thyroid tissue
Orbit Orbit
Haemangioma PNET
Vascular malformation Ewing sarcoma
Schwannoma Metastasis (neuroblastoma)
Optic nerve glioma Optic nerve glioma
Plexiform neurofibroma LCH
Teratoma
Lacrimal gland tumour
Dermoid cyst
Fibrous dysplasia
Fig. 7 Three examples of SE T2 appearances of different orbital
tumours in young children, presenting with rapidly progressive
proptosis. a 4-year old boy with right sided proptosis. SE T2 image
shows a high signal lesion in the medial quadrant of the orbit (arrow),
presumably extraconal. Biopsy: eRMS. b 1-year old boy with rapidly
progressive, left sided proptosis. SET2 shows intermediate signal
intensity lesion (arrow), with central necrosis (white arrow), in the
medial quadrant, compressing the lateral rectus muscle, presumably
extraconal. Final diagnosis: alveolar RMS, rare at such a young age. c
2-year old girl with rapidly increasing left sided proptosis. SE T2
shows a very low signal intensity tumour in the medio-inferior part of
the left orbit (arrow). Histology: primitive neuroendocrine tumour
(PNET)
Pediatr Radiol (2010) 40:1723–1738 1731into the PPS the tumour is classified as PM, with a worse
prognosis.
RMSofthelowerneckmayextendintothemediastinumor,
depending on the location, intraspinally. The latter finding will
change prognosis because this is categorized as a PM location.
Orbital RMS
Periorbital RMS originates from the eyelids and may
remain outside the orbit, i.e. in a preseptal location.
Intraorbital tumour includes extra- or intraconal tumour
location. Most RMS is locatedwithin the superonasal quadrant
of the orbit [48, 49]. Assessment of its relationship with the
extraocular muscles, the lacrimal gland, the lacrimal duct
system, the optic nerve, the globe and the apex of the orbit is
necessary (Table 1). Unlike PM locations, orbital RMS
seldom invades the skull base or extends intracranially [11,
49]. Extension through the inferior or superior orbital fissure
is rare, as is invasion of the adjacent paranasal sinuses.
Subtle bone deformity may be observed incidentally but
frank bone destruction with involvement of the bone
marrow and adjacent intracranial structures is rarely seen
in orbital RMS (Fig. 7). Bone invasion will change the
classification into a PM location. When bone destruction is
suspected on MRI additional CT is recommended to
confirm MRI findings and to exclude concomitant benign
disease, e.g., fibrous dysplasia.
Imaging differential diagnoses
Tumours of the head and neck in the paediatric population are
rare, representing about 2–3% of all head and neck tumours.
In many cases, imaging provides only a differential
diagnosis and imaging findings should be correlated with
clinical findings and discussed with the treating physician
in each individual case to decide whether a biopsy should
be taken or whether the child should be referred to a tertiary
centre. It is beyond the purpose of this paper to provide an
exhaustive overview of differential diagnostic considera-
tions, but Table 4 may serve as a guideline.
Malignant tumours other than RMS
Apart from HNRMS, other rapidly progressive malignant
childhood tumours of the head and neck may be encoun-
tered in young infants as well as older children. A few of
these tumours will be briefly reviewed and differential
diagnostic imaging findings will be addressed.
Nasopharyngeal carcinoma
Paediatric nasopharyngeal carcinoma (NPC) is rare
with <20% of NPC occurring in children [55]. Asymptom-
atic, large, unilateral or bilateral neck nodes are often the
first clinical symptom. Bilateral large neck nodes are very
uncommon in HNRMS, and this finding alone may direct
the diagnostic work-up towards NPC (Fig. 8)[ 56].
Malignant lymphoma
Malignant lymphoma of the head and neck is the most
common malignant head and neck tumour in children. It
may involve Waldeyer ring, the MS, the paranasal sinuses
and the orbits and often presents with bilaterally enlarged
neck nodes [57, 58]. Generally, malignant lymphoma has a
Fig. 8 Orbital eRMS with involvement of the roof of the orbit, a rare
form of orbital RMS, in an 8-year old boy, presenting with orbital pain
and proptosis. The bone invasion classifies the tumour as para-
meningeal, with a worse prognosis compared to orbital RMS.
a Coronal post-contrast SET1 image shows a large, strongly
enhancing lesion within the roof of the right orbit, extending into
the superior extraconal compartment (open arrow), suggesting a
primary bone tumour. Displacement of the eye ball downward and
laterally. b Additional CT (coronal multiplanar reconstruction after i.v.
contrast) confirmed bone involvement and local destruction with
intraorbital extention (arrow). From the imaging it was impossible to
differentiate between a primary bone tumour (MRI) or a primary
(atypical) orbital location with adjacent bone invasion (CT). The
location is not characteristic for RMS, which most often is within the
medial quadrant. At surgery the lesion was considered a primary bone
location. Histology: e-RMS
1732 Pediatr Radiol (2010) 40:1723–1738surprisingly smooth appearance on imaging and shows
moderate enhancement after IV contrast administration.
Homogeneous enlargement of the lymphoid ring of Waldeyer
in combination with unilateral or bilateral enlarged, homoge-
neous neck nodes may be seen in malignant lymphoma.
Central necrosis in the neck nodes is seen in a small minority
of patients.
Malignant lymphoma may also present with multiple
bone lesions and in these cases Langerhans cell histiocy-
tosis (LCH) or metastases of neuroblastoma should also be
considered.
A biopsy is required for final diagnosis, treatment being
different for NPC, non-Hodgkin lymphoma (NHL), LCH
and metastatic disease.
Ewing sarcoma/peripheral primitive neuroectodermal
tumour
Ewing sarcoma of bone presents as a very aggressive mass
lesion with permeative destruction of bone and invasion into
surrounding tissues. Only 4% of Ewing sarcoma of bone
presents in the head and neck. Imaging may show a variety of
signalintensitiesresemblingNHLorevenbenigndisease[59].
Peripheral primitive neuro-ectodermal tumour (pPNET)
occurs at an even lower incidence and may present as a well-
circumscribed soft-tissue mass, with low-to-intermediate
signal intensity on T2-Wimaging and moderate enhancement
after IV contrast administration [60]. A biopsy is mandatory
to confirm the diagnosis as there are no characteristic
imaging findings to differentiate these highly malignant
tumours from other sarcomas, HNRMS, extranodal malig-
nant lymphoma or even benign lesions.
Salivary gland tumors
Salivary gland tumours in children are rare, accounting for
<5% of all salivary gland tumours and <8–10% of all
paediatric head and neck tumours [61]. During infancy and
early childhood the most common lesions are vascular
malformations and lipomatous lesions. Sialoblastoma or
embryoma is a histologically benign salivary gland tumour
that is unique to children and has been reported only in
newborns and neonates. About 25% show features of
malignancy but distant metastases are rare. There is a high
risk of recurrence after incomplete surgical resection [61].
The majority of epithelial tumours occur after the age of
10–12 years and >90% originate within the parotid gland.
Unlike in adults, about 50% of parotid tumours in this group
of children are malignant. Pleomorphic adenoma is the most
common benign, while mucoepidermoid carcinoma is the
mostcommonmalignantepithelialtumour[61]. Sarcomas are
rare. A malignant salivary tumour in a younger child may
behave as a highly aggressive tumour with a poor prognosis.
Orbital tumours
Rapidly progressive proptosis in a child is an indication for
imaging. Although RMS is one of the most common orbital
malignant tumours, other rapidly growing malignant
lesions, such as malignant lymphoma, PNET and rhabdoid
tumour should also be considered (Fig. 9).
Chloroma or granulocytic sarcoma is the commonest
form of leukaemic involvement of the orbit, presenting as a
solid mass in young children with acute myeloid leukaemia,
which may precede the blast phase of the disease [62].
Primary bone lesions of the orbit may also result in
proptosis.Fibrousdysplasiaisabenign,expansile bonelesion
involving the craniofacial bones and skull base in the young
Fig. 9 Nasopharyngeal e-RMS in a 4-year old girl, presenting with
massive cervical lymphadenopathy, suggesting nasopharyngeal can-
cer. a Axial SET2 weighted image showing a high signal lesion
(arrow) within the right naso - oropharynx and enlarged retrophar-
yngeal lymph nodes (white arrow). b Coronal SET2 image showing
massive, bilateral cervical lymphadenopathy (open arrows & white
arrows). Final histology: e-RMS
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establish the definitive diagnosis. Malignant bone tumours
involving the orbit include Ewing sarcoma, malignant
lymphoma or metastatic disease [63]. LCH is an uncommon
disease characterized by clonal proliferation of Langerhans
cells. Aetiology and pathology are still conjectural. LCH
may present as a solitary bone lesion of the skull but also as
multifocal or systemic disease and must be included in the
differential diagnosis. Because of the space-occupying,
systemic and invasive-destructive characteristics of the
lesion(s), patients are often referred to the paediatric
oncologist or radiotherapist for management advice. In all
patients a biopsy is required to assess the final diagnosis.
Treatment and prognosis
Treatment of HNRMS requires a multidisciplinary approach,
where chemotherapy, surgery and radiation therapy each has
its own specific role. After the introduction of chemotherapy
and improvement in local therapy and diagnostic techniques,
survival has considerably improved over the last 30 years.
Whereas in the past only 25% survived, nowadays patients
with orbital primaries have up to 89% 3-year failure-free
survival [3] and those with parameningeal locations show a
5-year failure-free survival in 67% [4].
Orbital tumours have an excellent survival. Because the
majority of patients have received chemotherapy and
radiotherapy, an important number of patients encounter
major late effects [64]. A joint European-North American
analysis of their experience in orbital patients treated
according to consecutive protocols (1979–1992) suggests
that a subset of patients with orbital RMS can be cured
without systematic local therapy, although the total burden
of treatment must be taken into account when assessing the
implications for late sequelae [11]. Other approaches to
minimize late effects in this patients group include the use
of brachytherapy or proton therapy [65, 66].
Non-PM RMS also has a favourable outcome. More than
80% of patients with localized tumours are cured using
surgery and multiagent chemotherapy, with or without
radiotherapy [67]. Radiotherapy can be added for those with
IRS-II or IRS-III lesions, depending on the achievement of
complete remission by induction chemotherapy and cooper-
ative group guidelines. More recent COG studies will answer
the question whether early exposure to reduced dosages of
alkylating agents may improve event-free survival.
Parameningeal-located tumours have the least favourable
outcome of all HNRMS with a 5-year failure-free survival
of 67% [4]. Prognosis is strongly related to PM subsite and
presence or absence of meningeal involvement. Reviewing
data from three consecutive COG studies, Raney et al. [4]
identified three prognostic subsets: 20% of patients had
tumours in the middle ear/mastoid, nasopharynx/nasal
cavity (MEM, NNC) and PPS without meningeal involve-
ment (20% of patients) and showed excellent long-term
survival (92% at 5 years). Fifty-six-percent of all PMN
patients had either MEM- or NNC- or PPS-located tumours
and meningeal involvement or had tumours in the paranasal
sinuses or the pterygopalatine/infratemporal fossa (PNS,
PIF) without meningeal involvement. For this subgroup of
patients 5-year survival was intermediate, i.e. approximate-
ly 75%. Patients with PNS or PIF tumours and meningeal
involvement (24% of patients) had only a 57% survival rate
at 5 years. Treatment outcome for patients treated after
1977 was considerably better. One of the most important
reasons for this improvement was probably the availability
of improved diagnostic imaging studies (CT and MRI) and
the greater precision for determining appropriate volumes
for radiotherapy. Subsequent COG studies have shown that
Fig. 10 Follow-up of an 8-year-old girl who had a parameningeal left
sided eRMS 2 years previously with extension into the pterygopalatine
fossa. After a full course of chemotherapy she underwent AMORE
procedure. Clinically she is in complete remission 2 years after
surgery. Postoperatively a slowly regressing, enhancing lesion has
been present at the level of the left pterygoid, considered to be scar
tissue. a Routine follow-up MRI at 2 years. Axial SE T1-W image
shows abnormal low signal within fat marrow of left zygoma with
subtle intraorbital soft-tissue extension (arrow). b Coronal contrast-
enhanced fat-saturated SE T1-W image shows enhancement of the
zygomatic lesion (open arrow). Inferomedially the residual disease
(white arrow) is unchanged compared to previous MRI. c Additional
axial CT 2 months later, shows local cortical destruction (arrow).
Biopsy showed recurrent eRMS
1734 Pediatr Radiol (2010) 40:1723–1738whole-brain radiotherapy and intrathecal chemotherapy are
not an essential part of the therapeutic regimen in patients
with PMN RMS and therefore are no longer routinely used,
resulting in an important reduction of late adverse effects in
this patient category.
Regionallymphnodeinvolvementisrelativelyrarewithan
incidence of about 17% at diagnosis [4]. Involved lymph
node sites should receive radiotherapy. Apart from the
primary site, involvement of lymph nodes and IRSG,
histology and age also contribute to overall outcome. The
embryonal subtype has a better prognosis than alveolar RMS
and young age (<10 years) is a favourable prognostic factor.
Fifteen-percent of patients with RMS have metastatic
disease at first presentation. A recent pooled analysis from
the United States and European co-operative groups has
shown that the lungs are the most commonly involved
distant site (47%), followed by bone marrow (38%), bone
(34%) and distant nodes (26%). Prognosis appeared to be
strongly correlated with age, site, bone and/or bone marrow
involvement and the number of involved sites [45]. As the
majority of HNRMS patients survive, prevention of late
adverse effects is of utmost importance. However, adequate
local therapy often includes radiotherapy in this patient
group with a mean age of 5–6 years.
Therefore the ablative surgery, moulage brachytherapy
and surgical reconstruction (AMORE) procedure was
introduced in our institute in 1991 [54, 68]. After careful
staging of children with histologically proven HNRMS,
chemotherapy courses are given according to SIOP (or
currently EpSSG) protocols. Imaging is repeated during
chemotherapy and, after completion of the first cycle,
residual disease is evaluated. Children who do not have
evidence of skull base or intracranial extension of their
residual tumour mass after induction chemotherapy are
eligible for this procedure. Our results are encouraging in
that children who were enrolled in the AMORE procedure
have comparable survival and fewer complications than
those who had external beam radiation therapy [69].
Post-treatment follow-up
During chemotherapy, in addition to a slow or rapid
reduction in tumour volume, the tumour appearances may
change. On MRI a change from high to low signal intensity
on T2-W imaging as well as alteration of the enhancement
pattern may be observed. The exact meaning of these
changes is not well-understood, but probably relates to
tumour necrosis, decrease in tumour vascularity and
reactive changes of the surrounding tissues.
On the contrary, radiation and/or chemotherapy may
invoke significant changes in tumour viability with only
minimal changes in morphology, not recognized on routine
MRI [70]. An early study suggested that patients with
residual lesions after completing treatment were more at
risk of tumour recurrence than patients in whom no residual
lesions are seen on cross-sectional imaging [71]. A more
recent study, however, showed that tumour response to
induction chemotherapy had no effect on event-free
survival [72]. Furthermore, the presence or absence of a
residual lesion after completion of therapy did not appear to
have any impact on prognosis in a recent analysis by COG
[73]. It would therefore be helpful to have a more sensitive
tool to discriminate nonviable tumour necrosis or scar
tissue from viable residual tumour.
Routine MRI techniques fail to differentiate tumour
activity in a residual lesion from fibrosis, but a recent
publication suggests excellent discrimination between via-
ble and nonviable tissue by DWI [28]. DCE MRI may be
useful to differentiate complete from partial remission after
treatment but there is considerable overlap in enhancement
patterns between benign and malignant tumours [12, 74].
Up to now MR-spectroscopy remains unsuitable because of
the complex anatomy of the head and neck area.
18FDG PET-CT seems to be very promising in deter-
mining the nature of residual lesions but has the disadvan-
tages that it is a long examination and that it exposes young
patients to ionizing radiation [20, 75]. However, this may
be a relative contra-indication: in terms of risk-benefit PET-
CT may be more useful to these children with a malignancy
than omitting the PET-CT study. Although PET-CT seems
to provide additional information, it is still optional in the
international studies on RMS.
After surgery, interpretation of mass lesions may be
extremelydifficultonMRIorCTduetodistortionorresection
ofsofttissuesandbonylandmarks,thereplacementofexcised
structures with viable muscle during reconstructive surgery
andthe presenceofboneand/orfatflaps,whichmayresemble
tumour tissue. Therefore a baseline postoperative study is
needed to avoid pitfalls during follow-up, which we routinely
perform 3 months postoperatively. New techniques, such as
DWI or PET-CT may help to differentiate residual active
tumour from scar tissue after completion of treatment with the
aim of thereby avoiding early recurrence.
During follow-up, imaging is routinely repeated every
3 months during the first year following end of treatment,
every 4 months the 2nd and 3rd years and once per year for
2 more years.
Recurrent tumour is often suspected clinically but in a
minority of patients treatment failure is first demonstrated
by imaging (Fig. 10). Imaging may show subtle or large
mass lesions, which may be solitary or multiple and a
biopsy should be performed, whenever feasible, to assess
the nature of the suspicious mass. New imaging techniques
may help to confirm the nature of the mass in patients in
whom a biopsy is hazardous.
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MR imaging plays a crucial role in the primary evaluation
of head and neck tumours in the paediatric population as it
offers an exquisite depiction of soft-tissue tumours of the
face and orbit, the deep compartments of the head and neck
and the skull base. However, in the absence of character-
istic imaging appearances, histological diagnosis should be
obtained for all mass lesions whenever feasible (i.e. without
serious complications, e.g., blindness, gross haemorrhage,
cranial nerve damage). When no biopsy can be performed,
close follow-up by imaging should be considered. Rapid
progression can be differentiated from no perceivable
growth and imaging may thereby guide aggressive diag-
nostic and treatment strategies.
Staging of HNRMS is best achieved by a combination of
imaging techniques, where MRI offers a major contribution
to assessing local extent of the primary tumour and MRI
and US play an invaluable role in the assessment of cervical
lymph nodes. According to recent publications WBMRI
and PET-CT can make a major contribution to the
assessment of distant metastases.
After completion of treatment, MRI depicts the presence
or absence of residual masses and postsurgical anatomical
changes and thus serves as an excellent baseline for long-
term follow-up. Baseline MRI 3 months after extensive
surgery and/or radiotherapy may help to identify residual/
recurrent disease at an earlier stage.
In the near future new MRI techniques such as DWI,
WBMRI and/or PET-CT may play an important role in
monitoring initial therapy, differentiating the responders
from the nonresponders on chemotherapy, and may help
improve noninvasive discrimination between residual via-
ble and non-viable tumour masses in patients treated for
craniofacial RMS.
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